Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM (@dishakumarmd) 's Twitter Profile
Disha K. Narang, M.D.| Endocrinologist, Dipl. ABOM

@dishakumarmd

Obesity, and Culinary medicine doc. Trying to make the world healthier via weight management, habit change and food. Tweets are my own. IG: @dishanarangmd

ID: 1276299427

calendar_today17-03-2013 23:40:22

962 Tweet

949 Followers

981 Following

Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

Obesity management medications and metabolic bariatric surgery, better together 🤲 "Rather than viewing these highly effective and complementary treatment approaches as inevitable competitors, learning in whom, when, and how to combine them could be even more valuable and

Michael "Mike" Albert, MD (@michaelalbertmd) 's Twitter Profile Photo

Breaking: Lilly’s Zepbound® (tirzepatide) outperforms Wegovy® (semaglutide) in weight loss trial over 72 weeks 🚨 SURMOUNT-5 Top-line results: 🔹 Zepbound: 20.2% avg. weight loss (50.3 lbs) Vs. 🔹 Wegovy: 13.7% avg. weight loss (33.1 lbs) Zepbound, a dual GIP/GLP-1 agonist,

Breaking: Lilly’s Zepbound® (tirzepatide) outperforms Wegovy® (semaglutide) in weight loss trial over 72 weeks

🚨 SURMOUNT-5 Top-line results:
🔹 Zepbound: 20.2% avg. weight loss (50.3 lbs)
Vs. 
🔹 Wegovy: 13.7% avg. weight loss (33.1 lbs)

Zepbound, a dual GIP/GLP-1 agonist,
Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

Semaglutide is an option for treating obesity in patients with kidney failure on dialysis. This could significantly aid in their weight loss efforts and improve their chances of being listed for kidney transplantation. #semaglutide …ubs.pericles-prod.literatumonline.com/doi/10.1111/do…

Semaglutide is an option for treating obesity in patients with kidney failure on dialysis. This could significantly aid in their weight loss efforts and improve their chances of being listed for kidney transplantation. #semaglutide
…ubs.pericles-prod.literatumonline.com/doi/10.1111/do…
Ethan J. Weiss (@ethanjweiss) 's Twitter Profile Photo

The unique thing about GLP1RAs is that these drugs are not going away despite whatever hysteria is drummed up by skeptics . Unlike most drugs (eg, statins), people desperately want them, not because they will reduce the risk of serious chronic disease (they will)

Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

🚫 Why is aspirin 💊 not recommended for primary prevention in Type 2 diabetes? 15,480 adults with T2DM were randomized to aspirin 100mg had significantly lower rates of cardiovascular events 🫀 by 12% vs those on placebo. Why don't we give aspirin to everyone with T2DM? 🤔

🚫 Why is aspirin 💊  not recommended for primary prevention in Type 2 diabetes? 

15,480 adults with T2DM were randomized to aspirin 100mg had significantly lower rates of cardiovascular events 🫀  by 12% vs those on placebo.

Why don't we give aspirin to everyone with T2DM? 🤔
Daniel J Drucker (@danieljdrucker) 's Twitter Profile Photo

Label expansion as U.S. FDA approves the GIP-GLP-1 medicine tirzepatide for moderate to severe obstructive sleep apnea investor.lilly.com/news-releases/… $LLY Eli Lilly and Company

Label expansion as <a href="/US_FDA/">U.S. FDA</a> approves the  GIP-GLP-1 medicine tirzepatide for moderate to severe obstructive sleep apnea investor.lilly.com/news-releases/… $LLY <a href="/EliLillyandCo/">Eli Lilly and Company</a>
Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

Both GLP1-RA and SGLT2 inhibitors reduce cardiovascular events in people with Type 2 Diabetes. But does combination GLP1-RA + SGLT2 inhibitors reduce CV events more than GLP1-RA alone? Yes, according to a recent meta-analysis. In adults with type 2 diabetes, those adding

Both GLP1-RA and SGLT2 inhibitors reduce cardiovascular events in people with Type 2 Diabetes. 

But does combination GLP1-RA + SGLT2 inhibitors reduce CV events more than GLP1-RA alone? 

Yes, according to a recent meta-analysis.

In adults with type 2 diabetes, those adding
Nisha Patel, MD MS, Dipl of ABOM, CCMS (@drplantel) 's Twitter Profile Photo

Woohoo! Medicare has approved Zepbound for the treatment of sleep apnea (OSA)! THIS IS HUGE! Hopefully commercial insurances will soon follow. Let this be a reminder to people that GLP-1 medications are not just “weight loss” meds. They are cardiometabolic medications with more

Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

Obesity can be under or over-diagnosed when BMI alone as a criteria is used. Instead, measuring for excess body fat and evaluating for obesity-related diseases is a more accurate method of diagnosing obesity. See the new Definition and Diagnostic Criteria of Clinical Obesity

Obesity can be under or over-diagnosed when BMI alone as a criteria is used.

Instead, measuring for excess body fat and evaluating for obesity-related diseases is a more accurate method of diagnosing obesity.

See the new Definition and Diagnostic Criteria of Clinical Obesity
Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

There is a move toward revising the definition of obesity away from BMI and more toward better measurements of excess fat, based on this week's Lancet Commission. We can evaluate someone's level of excess fat by body through measuring someone's waist circumference or

There is a move toward revising the definition of obesity away from BMI and more toward better measurements of excess fat, based on this week's Lancet Commission.

We can evaluate someone's level of excess fat by body through measuring someone's waist circumference or
Daniel J Drucker (@danieljdrucker) 's Twitter Profile Photo

The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease U.S. FDA Novo Nordisk US

The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease <a href="/US_FDA/">U.S. FDA</a> <a href="/novonordiskus/">Novo Nordisk US</a>
Mark Lewis, MD, FASCO (@marklewismd) 's Twitter Profile Photo

There is a wisdom from the lived experience of patients that is not found in any medical textbook but that they teach to us in practice “Running, walking, and crawling are all moving forward, just at different speeds”

Scott Isaacs (@scottisaacsmd) 's Twitter Profile Photo

Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity. nejm.org/doi/full/10.10…

Treatment with #tirzepatide in the SUMMIT trial led to a lower risk of death from cardiovascular causes or worsening heart failure and improved health status in patients with #HFpEF and obesity.
nejm.org/doi/full/10.10…
Michael Weintraub, MD (@mweintraubmd) 's Twitter Profile Photo

Higher Body Mass Index is strongly linked to less sleep. Data from objective sleep monitoring with wearables from 120K individuals. Study link: buff.ly/3EKy2VV

Higher Body Mass Index is strongly linked to less sleep. 

Data from objective sleep monitoring with wearables from 120K individuals. 

Study link: buff.ly/3EKy2VV
Neil Stone (@drneilstone) 's Twitter Profile Photo

Because of conventional medicine -Your mother didn't die in childbirth -You didn't get polio as a kid -You've never seen smallpox -Your friend with type 1 diabetes is alive because of of insulin -You recovered from that infection because of antibiotics Science saves lives

Angela Fitch,MD (@drangelafitch) 's Twitter Profile Photo

Thank you Eli Lilly and Company for innovation on care delivery by providing access to the vial program. Now at a lower price (would have liked lower but 🙏 for a future of lower yet) and more dosing options! investor.lilly.com/news-releases/…

Michael "Mike" Albert, MD (@michaelalbertmd) 's Twitter Profile Photo

New research confirms the incredible weight management potential, cardiometabolic benefits, and safety of tirzepatide. Future incretins need to attempt a similar imbalanced agonism of GLP1/GIP. This gets me excited for SURPASS-CVOT & SURMOUNT-MMO! onlinelibrary.wiley.com/doi/full/10.10…

New research confirms the incredible weight management potential, cardiometabolic benefits, and safety of tirzepatide. Future incretins need to attempt a similar imbalanced agonism of GLP1/GIP. This gets me excited for SURPASS-CVOT &amp; SURMOUNT-MMO!
onlinelibrary.wiley.com/doi/full/10.10…
Michael "Mike" Albert, MD (@michaelalbertmd) 's Twitter Profile Photo

💡Can people with obesity reach a “normal” weight through diet & lifestyle alone? A massive UK study of 177,000+ adults says… not easily. 📉 Over 9 years (no surgery involved): For those with class 1 obesity (BMI 30–34.9): 🔹Men: 1 in 210 reached normal weight 🔹Women: 1 in 124

💡Can people with obesity reach a “normal” weight through diet &amp; lifestyle alone?

A massive UK study of 177,000+ adults says… not easily.
📉 Over 9 years (no surgery involved):
For those with class 1 obesity (BMI 30–34.9):
🔹Men: 1 in 210 reached normal weight
🔹Women: 1 in 124